U.S. FDA Approves UroGen's ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

1. UroGen Pharma's ZUSDURI received FDA approval for a specific bladder cancer treatment. 2. This marks a significant milestone as it's the first medication for recurrent LG-IR-NMIBC.

FDA Approval

+67.67%Current Return

-1.07%S&P 500

$7.174706/12 01:39 PM EDTEvent Start

$12.0306/13 07:56 PM EDTLatest Updated

2m saved

Insight

Article

FAQ

Why Very Bullish?

FDA approval typically leads to increased investor confidence and stock price surges, similar to past approvals by biotech firms that saw stock prices rise by over 20%.

How important is it?

FDA approval directly influences market perception and potential revenue, critically impacting URGN’s future earnings prospects.

Why Short Term?

Immediate market reactions to FDA approvals often manifest quickly, providing potential profit opportunities shortly after the announcement.

Related Companies

NDAQ:ALNY NDAQ:AVEO NDAQ:CLVS

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the U.S. Food and Drug Administration (FDA) approved ZUSDURI, the first and only FDA-approved medication for adults with recurrent LG-IR-NMIBC. ZUSDURI consists of mitomycin and sterile hydrogel, using UroGen's proprietary sustained release RTGel® technology. ZUSDURI has been designed.

U.S. FDA Approves UroGen's ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

FAQ

Why Very Bullish?

How important is it?

Why Short Term?

Related Companies

Related News